Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives

doi:10.7518/hxkq.2021.06.001

Abstract

Abstract:

Head and neck cancer is the seventh common cancer in the world, and various existing treatment strategies provide modest benefit for most patients with head and neck cancer. Meanwhile, therapeutic strategies lacking molecular typing significantly hinder the development of individualized treatment for head and neck cancer. In recent years, connected by preclinical models, the novel ideal has gradually reached a consensus in terms of facilitating inter-transformation of clinical problems and basic achievements. As a bridge between basic research and clinical transformation, patient-derived xenografts (PDX) models precisely replicate genetic characteristics and tumor evolution, which are displaying great vitality in elucidating the mechanism of tumorigenesis and progression. Moreover, cohorts composed of several PDX models highlight the unique advantages of mice for drug screening and biomarker analysis for patients. This ideal preclinical model explores potential treatment strategies suited the ethical standards as much as possible for patients.

Key words: patient-derived xenografts, head and neck cancer, heterogeneity, drug screening

CLC Number:

R 739.8

Zhang Zhiyuan, Sun Shuyang. Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives[J]. West China Journal of Stomatology, 2021, 39(6): 617-623.

References 42

1	Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phaseⅡstudy to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol, 2007, 25(16): 2171-2177.
2	Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50.
3	Burtness B, Harrington KJ, Greil R, et al. Pembrolizu-mab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928.
4	Ma J, Liu Y, Huang XL, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a Meta-analysis[J]. Oral Oncol, 2012, 48(11): 1076-1084.
5	Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
6	Byrne AT, Alférez DG, Amant F, et al. Interrogating o-pen issues in cancer precision medicine with patient-derived xenografts[J]. Nat Rev Cancer, 2017, 17(4): 254-268.
7	Rygaard J, Povsen CO. Heterotransplantation of a human malignant tumour to “nude” mice. 1969[J]. APMIS, 2007, 115(5): 604-608.
8	Cobb LM. The behaviour of carcinoma of the large bo-wel in man following transplantation into immune depri-ved mice[J]. Br J Cancer, 1973, 28(5): 400-411.
9	Pickard RG, Cobb LM, Steel GG. The growth kinetics of xenografts of human colorectal tumours in immune deprived mice[J]. Br J Cancer, 1975, 31(1): 36-45.
10	Selby PJ, Heyderman E, Gibbs J, et al. A human testicular teratoma serially transplanted in immune-deprived mice[J]. Br J Cancer, 1979, 39(5): 578-583.
11	Fiebig HH, Schuchhardt C, Henss H, et al. Comparison of tumor response in nude mice and in the patients[J]. Behring Inst Mitt, 1984(74): 343-352.
12	Osieka R. Human malignant melanoma: preclinical and clinical drug evaluation[J]. Behring Inst Mitt, 1984(74): 353-367.
13	Shorthouse AJ, Smyth JF, Steel GG, et al. The human tumour xenograft: a valid model in experimental chemotherapy[J]. Br J Surg, 1980, 67(10): 715-722.
14	Giovanella BC, Yim SO, Stehlin JS, et al. Development of invasive tumors in the “nude” mouse after injection of cultured human melanoma cells[J]. J Natl Cancer In-st, 1972, 48(5): 1531-1533.
15	Fogh J, Fogh JM, Orfeo T. One hundred and twenty-se-ven cultured human tumor cell lines producing tumors in nude mice[J]. J Natl Cancer Inst, 1977, 59(1): 221-226.
16	Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials[J]. Br J Cancer, 2001, 84(10): 1424-1431.
17	Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro[J]. Cancer Res, 2009, 69(8): 3364-3373.
18	Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features[J]. Cancer Res, 2007, 67(1): 398-407.
19	Poh A. Novartis compiles mouse avatar “encyclopedia”[J]. Cancer Discov, 2016, 6(1): 5-6.
20	Gao H, Korn JM, Ferretti S, et al. High-throughput s-creening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11): 1318-1325.
21	China plans large center for PDX models[J]. Cancer Discov, 2014, 4(2): 136-137.
22	Ledford H. US cancer institute to overhaul tumour cell lines[J]. Nature, 2016, 530(7591): 391.
23	Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research[J]. Cancer Discov, 2014, 4(9): 998-1013.
24	Stewart EL, Mascaux C, Pham NA, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma[J]. J Clin Oncol, 2015, 33(22): 2472-2480.
25	Lee HW, Lee JI, Lee SJ, et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are va-luable translational platforms for the development of personalized targeted therapy[J]. Clin Cancer Res, 2015, 21(5): 1172-1182.
26	Karamboulas C, Bruce JP, Hope AJ, et al. Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma[J]. Cell Rep, 2018, 25(5): 1318-1331.e4.
27	McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
28	Lilja-Fischer JK, Ulhøi BP, Alsner J, et al. Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts[J]. Acta Oncol, 2019, 58(10): 1489-1494.
29	Bi MJ, Zhang Z, Jiang YZ, et al. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance[J]. Nat Cell Biol, 2020, 22(6): 701-715.
30	Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xeno-patients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J]. Cancer Discov, 2011, 1(6): 508-523.
31	Ding L, Ellis MJ, Li SQ, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft[J]. Nature, 2010, 464(7291): 999-1005.
32	Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution[J]. Nat Genet, 2017, 49(11): 1567-1575.
33	Woo XY, Giordano J, Srivastava A, et al. Conservation of copy number profiles during engraftment and passa-ging of patient-derived cancer xenografts[J]. Nat Genet, 2021, 53(1): 86-99.
34	Facompre ND, Rajagopalan P, Sahu V, et al. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models[J]. Int J Cancer, 2020, 147(11): 3236-3249.
35	Arrowsmith J, Miller P. Trial watch: phaseⅡand phase Ⅲattrition rates 2011-2012[J]. Nat Rev Drug Discov, 2013, 12(8): 569.
36	Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71.
37	Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds[J]. Cell, 2016, 167(1): 260-274.e22.
38	Zhou R, Shi CJ, Tao WJ, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations[J]. Clin Cancer Res, 2019, 25(12): 3548-3560.
39	韩永. Ponatinib靶向抑制c-kit突变的头颈黏膜恶性黑色素瘤的实验研究[D]. 上海: 上海交通大学, 2017.
	Han Y. Ponatinib effectively inhibits c-kit mutations in patient derived tumor model of mucosal melanoma of head and neck[D]. Shanghai: Shanghai Jiao Tong University, 2017.
40	Mosier DE, Gulizia RJ, Baird SM, et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency[J]. Nature, 1988, 335(6187): 256-259.
41	McCune JM, Namikawa R, Kaneshima H, et al. The S-CID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function[J]. Scien-ce, 1988, 241(4873): 1632-1639.
42	Doulatov S, Notta F, Laurenti E, et al. Hematopoiesis: a human perspective[J]. Cell Stem Cell, 2012, 10(2): 120-136.

[1]	Feng Xiaodong.. Targeting-YAP/TAZ therapies for head and neck cancer, directly or indirectly? [J]. West China Journal of Stomatology, 2021, 39(5): 493-500.
[2]	Guo Wei. Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer [J]. West China Journal of Stomatology, 2020, 38(5): 489-494.
[3]	Liling Wu,Qingping Gao,Qiongyao Fu,Kun. Geng. Analysis of the risk factors of radiation-induced caries in patients with head and neck cancer [J]. West China Journal of Stomatology, 2019, 37(1): 87-91.
[4]	Xiaolei Gao, Xinhua Liang, Yaling Tang. Mechanisms and implications of cancer cell dormancy in head and neck carcinoma [J]. West China Journal of Stomatology, 2018, 36(1): 92-98.
[5]	Yan Liu, Mingxin Cao, Jiashun Wu, Xiaolei Gao, Xinhua Liang. Analysis of the current status of research on human papillomavirus-associated head and neck cancers based on recent Chinese literature [J]. West China Journal of Stomatology, 2017, 35(3): 301-310.
[6]	Tang Hong, Yang Kai, Zhao Cheng, Bai Yunlong, Huang Hao.. In situ visual imaging and in vivo distribution of head and neck squamous cell carcinoma in mice by nearinfrared fluorescent quantum dots epidermal growth factor receptor monoclonal antibody probe [J]. West China Journal of Stomatology, 2012, 30(6): 568-573.